Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Register Now: SMEs as a Source of Innovation – OHE Lunchtime Seminar, 4 July
20 June 2012
In response to the R&D productivity crisis affecting the pharmaceutical industry, “big pharma” is seeking to source therapeutics from small and medium sized enterprises (SMEs). In…
New OHE Consulting Report Explores the Many Faces of Innovation
19 June 2012
Now available from the OHE website, this report provides a clear explanation of the complex nature of innovation in medicines. A fully revised and expanded version…
Prospective Observational Studies: Whether, When and How to Use
18 June 2012
OHE’s Adrian Towse is co-author on the recent report by the ISPOR Good Research Practices Task Force on assessing comparative effectiveness using prospective observational studies.
New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?
14 June 2012
Just published are the results of an OHE Lunchtime Seminar given by Prof Riccaboni, from the University of Trento. In this publication, he explores whether R&D…
Join OHE for Its 50th Anniversary Annual Lecture with Sir Michael Rawlins
12 April 2012
Every year, OHE sponsors a lecture by an eminent economist or clinician that addresses an important current issue.
Overview of the Economics of the Market for Medicines in the UK
29 March 2012
OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2012 activities, he recently gave…
Spotlight on OHE: Valuing Spillovers, End-of-Life Decisions and Hospital Outcomes
20 March 2012
OHE’s outside activities in early 2012 focused on spillovers, HTA decision making, and measuring health outcomes.
The R&D Cost of a New Medicine
1 December 2012
The cost of R&D for a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because…
Is There a Productivity Crisis in Pharmaceutical R&D?
6 January 2012
This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar. It focuses primarily on…